聚(ADP-核糖)聚合酶抑制剂与DNA去甲基化剂联合治疗上皮性卵巢癌的协同效应
本研究评估PARP抑制剂奥拉帕利与DNA甲基转移酶抑制剂5-阿扎胞苷联合治疗上皮性卵巢癌的疗效。体外实验显示联合用药较单药显著抑制细胞增殖和迁移并诱导凋亡,体内细胞系及患者来源异种移植模型中也显著减少肿瘤重量和结节数。联合治疗可能成为上皮性卵巢癌的潜在治疗策略。
要点
- 奥拉帕利联合5-阿扎胞苷较单药显著抑制上皮性卵巢癌细胞增殖和迁移并诱导凋亡。
- 联合治疗在细胞系和患者来源异种移植模型中显著降低肿瘤重量和结节数。
- 联合治疗可能成为上皮性卵巢癌的潜在治疗策略。
核心结论
- PARP抑制剂与DNMT抑制剂联合治疗在上皮性卵巢癌细胞中具有显著抗肿瘤效应,该联合方案可能是上皮性卵巢癌的潜在治疗策略。
研究设计与样本
- 采用蛋白印迹分析和免疫组化评估上皮性卵巢癌细胞中DNMT1和PARP1蛋白表达水平。
- 在A2780、HeyA8、A2780-CP20和HeyA8-MDR上皮性卵巢癌细胞系中进行细胞增殖、凋亡和伤口愈合实验以评估奥拉帕利与5-阿扎胞苷联合效果。
- 使用上皮性卵巢癌细胞系异种移植模型和患者来源异种移植(PDX)模型进行体内实验。
主要发现
- 在A2780、HeyA8、A2780-CP20和HeyA8-MDR细胞系中,奥拉帕利联合5-阿扎胞苷较奥拉帕利或5-阿扎胞苷单药显著抑制细胞增殖和迁移并诱导凋亡。
- 在A2780细胞系异种移植模型和PDX模型中,联合治疗组肿瘤重量和结节数较对照组、奥拉帕利组和5-阿扎胞苷组显著降低。
- 联合治疗影响上皮性卵巢癌细胞内活性氧(ROS)及其相关蛋白包括p-ERK、NRF2、p-p38、HO-1和γH2AX的表达。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: Poly (ADP)-ribose polymerase inhibitors (PARPi) are effective clinical agents for treatment of epithelial ovarian cancer (EOC) harboring BRCA mutations as well as those without BRCA mutations. In this study, we evaluate the efficacy of combined PARPi and DNA methyltransferase inhibitor (DNMTi) in EOCs. METHODS: Expression levels of DNMT1 and PARP1 proteins in EOC cells were assessed using western blot analysis and immunohistochemistry. To evaluate the effects of co-treatment of PARPi (olaparib) and DNMTi (5-azacitidine, 5-AZA), we performed cell proliferation, apoptosis, and wound-healing assays in EOC cells. In addition, we performed in vivo experiments using both cell-line and patient-derived xenograft (PDX) models of EOC. RESULTS: The combination of olaparib and 5-AZA significantly inhibited cell proliferation and migration and induced apoptosis compared with olaparib or 5-AZA alone in EOC cell lines including A2780, HeyA8, A2780-CP20, and HeyA8-MDR. Moreover, in vivo experiments with this combination showed significantly decreased weight and nodule numbers of tumors in cell-line xenograft models with A2780 cells and a PDX model compared with control, olaparib, and 5-AZA groups. As a potential mechanism, the expression of intracellular reactive oxygen species (ROS) and its related proteins, including p-ERK, NRF2, p-p38, HO-1, and γH2AX, was affected in EOC cells. CONCLUSIONS: Co-treatment with PARPi and DNMTi had a significant anti-tumor effect in EOC cells. This combination might be a potential therapeutic strategy for EOCs.
引用
- Shim JI, Ryu JY, Jeong SY, et al. Combination effect of poly (ADP-ribose) polymerase inhibitor and DNA demethylating agents for treatment of epithelial ovarian cancer. Gynecol Oncol. 2022. PMID: 35305818. doi:10.1016/j.ygyno.2022.03.005
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。